Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding a specific plan transaction rather than a financial results report.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan ("The Plan"), which is notionally held in GSK Ordinary share ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports that on April 16, 2010, there was an increase in the notional allocation of Ordinary share ADRs for Ms. D Connelly at a price of $39.57 per ADR, following a re-valuation.
Investor Verification Checklist
- Verify the specific terms of the US Retirement Savings Plan regarding notional ADR allocations.
- Confirm the identity of Ms. D Connelly and her role as a person discharging managerial responsibility.
- Check the market price of GSK Ordinary share ADRs on April 16, 2010, to validate the $39.57 transaction price.
- Review the Disclosure and Transparency Rule 3.1.4R(1)(a) compliance requirements referenced in the filing.